Kobayashi Y, Watanabe N, Oshimi K
Department of Biomolecular Science, Faculty of Science, Toho University, Chiba, Japan.
Leuk Lymphoma. 1994 Jun;14(1-2):157-61. doi: 10.3109/10428199409049663.
The immunological findings and clinical course of 33 patients with granular lymphocyte-proliferative disorders (GLPD) are presented. Based on the surface phenotypes of peripheral blood granular lymphocytes (GL), the GLPD were divided into two groups, namely CD3+ T cell-lineage GLPD (T-GLPD) and CD3- CD16+ NK cell-lineage GLPD (NK-GLPD). Twenty-one patients had T-GLPD, and 12 had NK-GLPD. One patient with T-GLPD and two patients with NK-GLPD had progressive clinical courses and died of the disease despite receiving combination chemotherapy. Among eleven patients analysed for the expression of multidrug resistance P-glycoprotein, six of eight patients with T-GLPD and all three patients with NK-GLPD clearly expressed P-glycoprotein. Since patients with immature NK-GLPD appear to undergo a progressive clinical course, we suggest that therapeutic trials using P-glycoprotein blockers in addition to chemotherapy might be beneficial for such patients.
本文报告了33例颗粒淋巴细胞增殖性疾病（GLPD）患者的免疫学检查结果及临床病程。根据外周血颗粒淋巴细胞（GL）的表面表型，GLPD分为两组，即CD3+ T细胞系GLPD（T-GLPD）和CD3- CD16+ NK细胞系GLPD（NK-GLPD）。21例患者为T-GLPD，12例为NK-GLPD。1例T-GLPD患者和2例NK-GLPD患者临床病程呈进行性发展，尽管接受了联合化疗，仍死于该病。在分析了多药耐药P-糖蛋白表达情况的11例患者中，8例T-GLPD患者中的6例以及所有3例NK-GLPD患者均明显表达P-糖蛋白。鉴于不成熟NK-GLPD患者似乎临床病程呈进行性发展，我们建议除化疗外，使用P-糖蛋白阻滞剂进行治疗试验可能对这类患者有益。
